Search stocks

Find any stock by ticker or company name

Home

RLMD

Relmada Therapeutics, Inc. (RLMD)

NCM – Real vaqt narxi. Valyuta: USD

4.64

+0.17 (3.80%)

Bozor ochiq: Aug 12, 2026, 1:10 PM EDT

4.47

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

Home

RLMD

Relmada Therapeutics, Inc. (RLMD)

NCM – Real vaqt narxi. Valyuta: USD

4.64

+0.17 (3.80%)

Bozor ochiq: Aug 12, 2026, 1:10 PM EDT

4.47

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

11.08.2026

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

07.08.2026

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.

07.08.2026

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Videolar

No Data

There is no data to display